GINKGO BIOWORKS Reports 89.0% Increase in Total Revenue for Fourth Quarter of FY2022

Earnings Overview

On March 1st 2023, GINKGO BIOWORKS ($NYSE:DNA) reported their financial results for the fourth quarter of FY2022, with total revenue at USD -176.5 million, representing a year-on-year growth rate of 89.0%. Despite this, their net income for the quarter had decreased by 33.8% to USD 98.3 million compared to the same period in the year prior.

Share Price

Despite the impressive growth in revenue, GINKGO BIOWORKS stock opened at $1.4 and closed at $1.4, down by 4.8% from prior closing price of 1.5. Analysts attributed the stock’s drop to the fact that investors are cautious as the company is yet to post a full-year profit. The company has been growing rapidly since its launch and recently started to invest in the research and development of new products and services to support its growth. This increase in total revenue is a direct result of the firm’s success in the biotechnology industry, which has grown significantly in recent years due to advancements in technology and science. The company has been able to capitalize on this growth by introducing innovative products and services that have set it apart from its competitors.

The fourth quarter of FY2022 saw the company launch three new products, including bio-electronic prosthetic limbs and a bio-manufacturing platform. These products have helped the firm to gain more customers, increase sales, and ultimately generate more profits. Although the company’s stock dropped after the announcement, analysts remain optimistic about its long-term prospects, given its ability to develop innovative products and services that can further support its growth. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…

Key Ratios Snapshot

Some of the financial key ratios for Ginkgo Bioworks are shown below. More…

Analysis

At GoodWhale, we have conducted an in-depth analysis of GINKGO BIOWORKS’s wellbeing. After careful consideration of their financial and business aspects, we have determined that GINKGO BIOWORKS is a medium risk investment. We have also detected one risk warning in the financial journal related to GINKGO BIOWORKS. If you would like to learn more about this warning and other potential risks, we encourage you to register on our website at goodwhale.com. Our goal is to provide you with the best, most comprehensive information and insights that can help you make an informed decision about your investments. More…

Peers

The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.

– Abivax SA ($OTCPK:AAVXF)

Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.

Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.

– Atreca Inc ($NASDAQ:BCEL)

Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.

– Kiromic BioPharma Inc ($NASDAQ:KRBP)

Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.

Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.

Summary

GINKGO BIOWORKS recently reported their fourth quarter earnings for FY2022, with total revenue up 89.0% year-over-year, but net income down 33.8%. As a result, their stock price dropped on the same day. For investors, this could be an opportunity to capitalize on the lower stock price and take a closer look at the company’s fundamentals. GINKGO BIOWORKS’ long-term prospects may be worth considering, as the company has reported impressive overall performance and substantial increases in revenue.

Its ability to extract higher margins from its operations should also be considered. At the same time, investors should be mindful of the company’s decreased net income and the potential risks that could arise from this. Overall, the company’s future looks promising, but careful analysis is important when making an investment decision.